Skip to main
  1. Stocks
  2. Diebold Nixdorf Inc
  3. Forecast
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf is supported by improving operating execution, with service gross margins rising to 27.7%, retail revenue up 16% year over year, and notable wins such as 520 recyclers at a top North American bank and a 6,000-lane self-checkout refresh in Europe. The banking franchise remains strategically important because it generates most revenue, and management expects 95%-98% of contracts to include memory escalators by the end of 4Q, which should ease a roughly $10M 2H headwind and support better pricing and margins. Confidence is reinforced by strong cash generation, about $495M of liquidity, net leverage of 1.5x, and a new $250M buyback authorization that signals a commitment to returning capital while the Euronet collaboration could expand integrated ATM solutions.

Bears say

Diebold Nixdorf is facing a कमजोर fundamental setup because its latest beat was overshadowed by a sharp reset in 2026 guidance, with EBITDA cut to $490M-$510M, EPS to $4.50-$4.85, and free cash flow to $190M-$210M as mix shifts, memory inflation, and banking deal delays weigh on results. Margin quality is deteriorating, as corporate gross margin fell to 25.3%, retail gross margin dropped 400 bps year over year to 20.7%, and the company no longer expects its targeted ~50 bps of full-year service margin expansion, signaling limited pricing power. The negative view is reinforced by falling ATM demand, competitive pressure from alternative products, lower expected upgrade activity, and additional FX and liquidity risks tied to concentrated ownership and thin trading volume.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

DBD Analyst Forecast & Price Prediction

Get the latest DBD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


DBD Analyst Forecast & Price Prediction

Get the latest DBD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DBD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DBD stock data and trends